Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 19, 2001, Pages 20-25

  Pollack, M H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; BARBITURIC ACID; BENZODIAZEPINE; BUSPIRONE; CHLORDIAZEPOXIDE; DIAZEPAM; FLUOXETINE; IMIPRAMINE; LORAZEPAM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; OXAZEPAM; PAROXETINE; PLACEBO; SEROTONIN 1A AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; ANXIETY NEUROSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG PREFERENCE; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; COMORBIDITY; CRITICAL PATHWAYS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MENTAL DISORDERS; PRACTICE GUIDELINES; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0034811838     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (92)

1. A comparison of panic disorder and generalized anxiety disorder
2. Generalized anxiety and generalized anxiety disorder: Description and reconceptualization
3. The clinical presentation of generalized anxiety in primary-care settings: Practical concepts of classification and management
4. Long-term pharmacological treatment of generalized anxiety disorder
5. Physical illness as an outcome of chronic anxiety disorders
6. Explained and unexplained medical symptoms in generalized anxiety and panic disorder: Relationship to the somatoform disorders
7. Comorbidity of DSM-III-R major depressive disorder in the general population: Results from the US National Comorbidity Survey
8. Comparing primary and secondary generalized anxiety disorder in a long-term naturalistic study of anxiety disorders
9. Comorbidity as a fundamental feature of generalized anxiety disorders: Results from the National Comorbidity Study (NCS)
10. The epidemiology of pure and comorbid generalized anxiety disorder: A review and evaluation of recent research
11. Time to recovery, chronicity, and levels of psychopathology in major depression: A 5-year prospective follow-up of 431 subjects
12. Remission and relapse in major depression: A two-year prospective follow-up study
13. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey
14. Role impairments associated with pure and comorbid generalized anxiety disorder and major depression in two countries
15. The structure of the genetic and environmental risk factors for six major psychiatric disorders in women: Phobia, generalized anxiety disorder, panic disorder, bulimia, major depression, and alcoholism
16. A variable-number-tandem-repeat of the serotonin transporter gene and anxiety disorders
17. Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: A meta-analysis
18. SSRls and SNRIs: Broad spectrum of efficacy beyond major depression
19. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder
20. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial
21. Efficacy of venlafaxine XR in social adjustment in patients with generalized anxiety disorder
22. The effects of venlafaxine on social activity level in depressed outpatients
23. Treating depression to remission
24. Treatment of major depression: Is improvement enough?
25. Goal of antidepressant therapy: Response or remission and recovery?
26. Clinical guidelines for establishing remission in patients with depression and anxiety
27. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder
28. Benzodiazepines
29. Anxiety disorders
30. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications, 4: Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders
31. Phenomenology and course of generalised anxiety disorder
32. Abecarnil for the treatment of generalized anxiety disorder: A placebo-controlled comparison of two dosage ranges of abecarnil and buspirone
33. The uses of buspirone in psychiatry
34. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms: A meta-analysis of eight randomized, controlled studies
35. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy
36. The functional anatomy, neurochemistry, and pharmacology of anxiety
37. Long-term buspirone therapy for chronic anxiety: A multicenter international study to determine safety
38. The clinical course and long-term management of generalized anxiety disorder
39. Antidepressant selection: Proceedings from a TCA/SSR1 Consensus Conference
40. Attaining remission in generalized anxiety disorder: Venlafaxine extended release comparative data
41. Differential efficacy of venlafaxine ER and fluoxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder
42. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety
43. One-year costs of second-line therapies for depression
44. Paroxetine efficacy in the treatment of generalized anxiety disorder
45. Paroxetine treatment of GAD: A double-blind, placebo-controlled trial
46. Fast-onset antidepressants
47. The efficacy of newer antidepressants in the treatment of chronic pain: A review of current literature
48. Evidence-based data on pain relief with antidepressants
49. Venlafaxine hydrochloride and chronic pain
50. The use of mirtazapine in a patient with chronic pain
51. Venlafaxine for the treatment of chronic pain
52. Painful peripheral diabetic neuropathy treated with venlafaxine HCl extended release capsules
53. Venlafaxine HCl in the treatment of painful peripheral diabetic neuropathy
54. Efficacy of venlafaxine and placebo during long-term treatment of depression: A pooled analysis of relapse rates
55. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression
56. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia
57. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder
58. Venlafaxine ER in the treatment of generalised anxiety disorder: A 24-week placebo-controlled dose-ranging study
59. A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression
60. Paroxetine: An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders
61. Paroxetine in the treatment of melancholia and severe depression
62. Venlafaxine and paroxefine in treatment -resistant depression: Double-blind, randomised comparison
63. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia
64. Efficacy of venlafaxine ER in social adjustment in patients with generalized anxiety disorder
65. SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability
66. Extended antidepressant maintenance and discontinuation syndromes
67. Optimal dose regimen for paroxetine
68. Poor response to fluoxetine: Underlying depression, serotonergic overstimulation, or a "therapeutic window"?
69. Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo
70. A double-blind, placebo-controlled dose-finding study with sertraline
71. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression
72. Low-dose fluoxetine therapy for depression
73. Dose-response relationship with venlafaxine
74. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression
75. Dose-response efficacy of long-term treatment of venlafaxine extended-release in generalized anxiety disorder
76. Antidepressant drug selection: Criteria and options
77. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia
78. A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression
79. Drug-drug interactions involving antidepressants: Focus on venlafaxine
80. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: Focus on venlafaxine
81. The longitudinal course and outcome of panic disorder
82. Brief cognitive therapy for panic disorder: A randomized controlled trial
83. Cognitive-behavioral group therapy for panic disorder in the general clinical setting: A naturalistic study with 1-year follow-up
84. A comparison of focused and standard cognitive therapy for panic disorder
85. Biofeedback treatments of generalized anxiety disorder: Preliminary results
86. Applied relaxation vs cognitive therapy in the treatment of generalized anxiety disorder
87. The treatment of anxiety disorders in a primary care HMO setting
88. Factors predicting the clinical course of generalised anxiety disorder